Login to Your Account



Pharma: Clinic Roundup


Tuesday, March 19, 2013

• Ferring Pharmaceuticals SA, of Saint Prex, Switzerland, presented data at the European Association of Urology 2013 annual meeting in Milan, Italy, showing that degarelix (Firmagon), a gonatropin-releasing hormone antagonist for prostate cancer, may be associated with a lower risk of a cardiovascular event or death compared to luteinizing hormone-releasing agonists.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription